Enhertu granted Priority Review in the US for the treatment of HER2-positive metastatic gastric cancer
AstraZeneca and Daiichi Sankyo were granted priority review by the FDA for Enhertu to treat HER2-positive gastric or gastroesophageal junction cancer, with... Read More
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Gastric cancer patients treated with Enhertu in a recent study had favorable response rates, survival and duration of response as compared to... Read More
Enhertu granted Orphan Drug Designation in the US for gastric cancer
AstraZeneca and Daiichi Sankyo won breakthrough designation and orphan drug designation from the FDA for Enhertu in treating HER2-positive gastric cancer, which... Read More
